Webdisclosure.com

NEWRON PHARMACEUTICALS S.P.A.

09/10/2023 12:45

EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

04/10/2023 07:00

EQS-News: Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

02/10/2023 07:00

EQS-News: Newron appoints Margarita Chavez as board advisor

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

04/08/2023 07:00

EQS-News: Newron announces H1 2023 results and provides R&D update

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

15/05/2023 07:00

EQS-News: Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

03/05/2023 07:00

EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

02/05/2023 07:00

EQS-News: Newron announces Senior Management Team changes

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

18/04/2023 12:15

EQS-News: Newron announces AGM 2023 results

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

28/03/2023 12:30

EQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

20/03/2023 07:00

EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

1
2
3
4
5
6
7
8
9
10